In August, Exact Sciences stock climbed when a Rodman & Renshaw analyst upgraded the company’s shares from “market perform” to “market outperform,” meaning that it is expected to perform marginally better than the market as a whole.
“Starting the trial is a major milestone for the company that wouldn’t have been possible without the outstanding team we’ve built,” said Kevin T. Conroy, Exact Sciences’ president and CEO, in a statement released along with the secondquarter results. “We are focused now on the trial’s successful completion and delivering to market a patient-friendly screening test that enables the early detection of the disease.”
|Title||Expiration Date||CME Credits|
|Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast Cancer||May 30, 2018||2.0|
|Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers||May 30, 2018||1.5|